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Abstract
Background: Electrocardiographic measures of left ventricular hypertrophy (LVH) are used as predictors of cardiovascular
risk. We combined linkage and association analyses to discover novel rare genetic variants involved in three
such measures and two principal components derived from them.
Methods: The study was conducted among participants from the Erasmus Rucphen Family Study (ERF), a
Dutch family-based sample from the southwestern Netherlands. Variance components linkage analyses were
performed using Merlin. Regions of interest (LOD > 1.9) were fine-mapped using microarray and exome sequence data.
Results: We observed one significant LOD score for the second principal component on chromosome 15 (LOD score
= 3.01) and 12 suggestive LOD scores. Several loci contained variants identified in GWAS for these traits; however, these
did not explain the linkage peaks, nor did other common variants. Exome sequence data identified two associated
variants after multiple testing corrections were applied.
Conclusions: We did not find common SNPs explaining these linkage signals. Exome sequencing uncovered a relatively
rare variant in MAPK3K11 on chromosome 11 (MAF = 0.01) that helped account for the suggestive linkage peak observed
for the first principal component. Conditional analysis revealed a drop in LOD from 2.01 to 0.88 for MAP3K11, suggesting
that this variant may partially explain the linkage signal at this chromosomal location. MAP3K11 is related to the JNK
pathway and is a pro-apoptotic kinase that plays an important role in the induction of cardiomyocyte apoptosis in
various pathologies, including LVH.
Background
Left ventricular hypertrophy (LVH) is a predictor of in-
creased cardiovascular morbidity and mortality [1]. Those
with LVH have a 2-fold increased risk of adverse events,
particularly ischemic heart disease and chronic heart fail-
ure [2, 3]. Increased left ventricular mass maintains cardiac
pump performance in response to cardiovascular insults,
such as coronary heart disease [3, 4]. Risk factors for LVH
are elevated systolic blood pressure, obesity, hypertension,
insulin resistance, valvular heart disease and advanced age,
among others [2, 5, 6]. LVH proxy measurements can be
assessed through noninvasive methods, such as echocardi-
ography and magnetic resonance imaging, however, elec-
trocardiographic measurements are the most used
worldwide [7]. LVH proxy measurements include calcula-
tions of the Sokolow-Lyon index (SL), the Cornell voltage
product (CV) and the 12-lead sum QRS product (12LS).
Several studies have demonstrated that genetic factors in-
fluence electrocardiographic and echocardiographic mea-
sures of LVH [2, 4, 5, 8, 9]. We recently demonstrated that
these measures contain a substantial heritable component
(SL = 0.46, 12LS = 0.49 and CV = 0.34) [10].
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Genome-wide linkage analyses, candidate gene associ-
ation studies, genome-wide association studies (GWAS)
and gene mapping have been conducted to identify
genes influencing LVH. In the first GWAS of these
traits, two loci, PTGES3 and NMB, reached genome-
wide significance. IGF1R and SCN5A were identified and
replicated without reaching genome-wide significance
[5]. Recently, an expanded GWAS detected a number of
novel loci influencing CV, SL, and 12LS [11]. Among
these were 32 loci containing genes with known cardiac
function, coding for cardiac sarcomere components or
related to cardiac myocyte function. Evidence for linkage
of echocardiographic LV mass to chromosome 5 (LOD
score = 1.6) and electrocardiographic LV mass to
chromosome 7 (LOD score = 1.67) [8] and chromosome
12 (LOD score = 2.19 and 3.11) [8, 12] were reported in
linkage studies, with the strongest evidence for chromo-
some 12 [3]. As is the case for other complex outcomes,
most candidate genes studies have not been replicated
and do not reach genome-wide significance [3].
Exome sequencing has been successfully used for
Mendelian disorders [13]. More recently, this technology
has been extended to the analysis of non-Mendelian
diseases and complex traits, as rare variants with large
effects can contribute to the heritability of common
traits. The aim of this study was to discover rare variants
by linkage analysis in a large family-based study, the
Erasmus Rucphen Family (ERF) study. Linked regions
were fine-mapped in detail using microarray data and
exome sequencing.
Methods
Study population
The ERF study is a family-based study including over
3000 participants descendant from 22 couples that lived
in the Rucphen region in the southwest Netherlands in
the nineteenth century [14]. All descendants of those
couples were invited to visit the clinical research center
in the region where they were examined in person [15].
Interviews at the time of blood sampling were per-
formed by medical practitioners and included questions
on current medication use and medical history [16].
Additionally, participants were asked to bring their
current medications with them to the study center; these
were cross-referenced with general practitioner and
pharmacy records. Height and weight were measured
with the participant in light underclothing and body
mass index (kg/m2) was computed. Blood pressure was
measured twice on the right arm in a sitting position
after at least 5 min rest, using an automated device
(OMRON 711, Omron Healthcare, Bannockburn, IL,
USA). The average of the two measures was used for
analysis. Hypertension status was identified through the
use of antihypertensive medication and/or through the
assessment of blood pressure measurements according to
the guidelines of the World Health Organization [17]. The
Medical Ethics Committee of the Erasmus University
Medical Center approved the ERF study protocol and all
participants, or their legal representatives, provided
written informed consent.
ECG interpretation and measurements
Examinations included 12-lead ECG measurements. A
10 s 12-lead ECG (on average, 8 to 10 beats) was recorded
with an ACTA-ECG electrocardiograph (Esaote, Florence,
Italy) with a sampling frequency of 500 Hz. Digital mea-
surements of the ECG parameters were made using the
Modular ECG Analysis System (MEANS) [18, 19]. Briefly,
MEANS operates on multiple simultaneously recorded
leads, which are transformed to a detection function that
brings out the QRS complex and the other parts of the
signal. MEANS determines common onsets and offsets
for all 12 leads together on one representative averaged
beat, with the use of template matching techniques. The
measurement and diagnostic performance of MEANS has
been extensively evaluated, both by the developers and by
others [19–22]. The MEANS criteria for MI are mainly
based on pathological Q waves, QR ratio, and R-wave pro-
gression [20]. A cardiologist, specialized in ECG method-
ology, ascertained the final diagnosis of MI.
MEANS was used to measure QRS complex duration
and the three LVH proxies. Sokolow-Lyon was defined as
the sum of the S wave in V1 plus the R wave in V5 or V6,
Cornell as the sum of R in aVL and S in V3, and 12-lead
as the sum of R to S in all 12 leads; these three voltages
were then multiplied by QRS duration to obtain voltage-
duration products as an approximation of the area under
the QRS complex [21–23]. Principal component (PC) ana-
lysis was applied to the three original measurements (SL,
12LS and CV) to capture the correlation structure
between traits. Two PCs, PC1 and PC2, captured more
than 94% of the total variance and were also assessed as
phenotypes in these analyses. All traits were adjusted for
sex, age, BMI and height and the residuals were rank
transformed prior to analysis.
Genotyping and statistical analysis of the linkage study
Illumina’s HumanHap6k Genotyping BeadChip (6 K
Illumina Linkage IV Panels®) was used for genotyping
for the linkage analyses. All genotyping procedures were
performed according to the manufacturer’s protocols.
Only markers with a minor allele frequency (MAF) >
0.05 were selected for further analysis. Genotyping er-
rors leading to Mendelian inconsistencies were detected
using PedCheck [24]. Unlikely double recombination
events were detected using MERLIN [25]. All detected
errors were eliminated from the data. A total of 5250
autosomal SNPs with a call rate greater than 95% were
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utilized for the linkage analyses. Among the 2385 indi-
viduals who were phenotyped for LVH measures, 1860
people also had genotype data and were included in the
linkage study. Variance component multipoint linkage
was performed using the –vc option in MERLIN v.1.0.1
[25, 26]. This program calculates exact IBD sharing prob-
abilities using the Lander-Green algorithm, requiring
restrictions on pedigree size. Because of this, the single
ERF pedigree with multiple loops was split into non-
overlapping fragments of no more than 18 bits with the
help of the PedSTR program [27].
Regions of interest with LOD > 1.9 were selected for fur-
ther analysis. Borders of the linkage areas were defined as
LOD score minus 2 support intervals (LOD-2 SI) around
the linkage peaks. Genes within the LOD-2 SI were anno-
tated using SCAN (SNP and CNVAnnotation Database).
Genotyping and statistical analysis of the association
study
Of 2385 phenotyped people, dense genotypes were avail-
able for 2128 subjects, typed on 3 different genotyping
platforms (Illumina 318 K, Illumina 370 K and Affyme-
trix 250 K), which were merged first (median number of
quality controlled SNPs per individual = 325,500) and
then ~ 2.54 million SNPs were imputed using MACH
(v1.0.16) [28, 29], with the HapMap build 36 (release 22)
CEU population as reference. Within each genotyping
batch, only SNPs with a call rate > 98%, MAF > 1% and
Hardy-Weinberg Equilibrium P-value > 10− 6 were used
for imputations. To account for relatedness, a genomic
kinship matrix was computed in GenABEL [30]. This
matrix was then incorporated into linear mixed-effects
regression models, as implemented in ProbABEL [31],
which were used to assess the association of variants in
the LOD-2 SI with the LVH phenotypes. P-values were
adjusted with the FDR-based q-value technique [32].
Exome sequencing
The exomes of 1336 individual from the ERF population
were sequenced “in-house” at the Center for Biomics of
the Department of Cell Biology of the Erasmus MC, the
Netherlands, using the Agilent version V4 capture kit on
an Illumina HiSeq 2000 sequencer using the TruSeq Ver-
sion 3 protocol. Mean depth base was 74.23× (median =
57×) and mean depth region was 65.26× (median =
52.87×). The sequence reads were aligned to the human
genome build 19 (hg19) using BWA and the NARWHAL
pipeline [33, 34]. The aligned reads were processed further
using the IndelRealigner, MarkDuplicates and TableRecali-
bration tools from the Genome Analysis Toolkit (GATK)
and Picard (http://broadinstitute.github.io/picard/) to re-
move systematic biases and to recalibrate the PHRED qual-
ity scores in the alignments. Genetic variants were called
using the Unified Genotyper tool of the GATK. About
1.4 million Single Nucleotide Variants (SNVs) were
called and, after removing the low quality variants
(QUAL < 150), we retrieved 577,703 SNVs in 1309 in-
dividuals. ECG and covariate data were available for
1072 of these samples. Further, for comparison and to
predict the functionality of the variants, annotations
were also performed using the dbNSFP (database of
human non-synonymous SNPs and their functional
predictions, http://varianttools.sourceforge.net/Annota-
tion/DbNSFP) and Seattle (http://snp.gs.washington.edu/
SeattleSeqAnnotation138/) databases. These databases
gave functional prediction results from four different pro-
grams, PolyPhen-2, SIFT, MutationTaster and LRT, apart
from gene and variant annotations.
We employed a Bonferroni correction for the number
of deleterious mutations selected for each trait to correct
for multiple comparisons in the exome data: 101 for SL
(P-value = 4.9 × 10− 4), 98 for CV (P-value = 5.1 × 10− 4)
and 60 for 12 LS (P-value = 8.3 × 10− 4). For the PCs, the
numbers were 141 for PC1 (P-value = 3.5 × 10− 4) and 71
for PC2 (P-value = 7.0 × 10− 4).
Replication
Four SNPs (rs139580877, rs138968470, rs35996030 and
rs142551296) were selected for replication in the Rotter-
dam Study (RS). The Rotterdam Study is a prospective
cohort study ongoing since 1990 in the city of Rotter-
dam in the Netherlands [35].
Exomes from 1764 individuals from the RS population
were sequenced at an average depth of 20× using the
Nimblegen SeqCap EZ V2 capture kit on an Illumina
HiSeq 2000 sequencer and the TrueSeq Version 3 proto-
col. The sequence reads were aligned to hg19 using
BWA. Subsequently, the aligned reads were processed
further using Picard, SAMtools and GATK. Genetic vari-
ants were called using the Unified Genotyper Tool from
GATK. Samples with low concordance to genotyping
array (< 95%), low transition/transversion ratio (< 2.3),
high heterozygote to homozygote ratio (> 2.0) and low
call rate (< 80%) were removed from the data. SNVs with
a low call rate (< 90%) and out of HWE (P-value < 10− 6)
were also removed from the data. The final dataset con-
sisted of 635,814 SNVs in 1450 individuals with
complete phenotype and covariate data.
One SNP, rs139580877, was not available in the
Rotterdam Study exome data. This variant was imputed
using the GIANT 1000 Genomes Phase I Version 3 All
reference panel, as previously described [36]. In brief,
after filtering SNPs genotyped with the Illumina v3
Infinium II HumanHap550 microarray for deviations
from Hardy-Weinberg proportions (P < 1 × 10− 6) , call
rate (< 98%), MAF (< 0.01), and Mendelian errors (> 100),
MACH was used to perform the imputations.
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Results
Table 1 shows characteristics of the participants in the
LVH linkage, microarray, and exome sequence analyses.
The proportion of LVH cases for each proxy measure
was determined using published cut-off values [37, 38].
There were no significant differences between these
overlapping groups. Table 2 shows the correlation be-
tween the traits (r = 0.76 in the adjusted model for SL
and 12LS, 0.17 between SL and CV, and 0.48 for CV and
12LS). Table 3 shows the loadings of the three LVH
proxies (SL, CV, 12LS) to the two PCs that were con-
structed. PC1 predominantly captured SL and 12LS,
while PC2 correlated strongly with CV and moderately
with SL. Table 4 shows the linkage results for the LVH
proxy measures, which yielded a total of seven regions
with suggestive LOD scores (LOD > 1.9). SL was linked
to three regions, with the highest LOD score for
chromosome 20 (LOD = 2.64) and two additional regions
on chromosomes 4 (LOD = 2.14) and 15 (LOD = 1.92).
Suggestive LOD scores for CV were seen on chromo-
somes 1 (LOD = 2.4) and 6 (LOD = 2.17). There was sug-
gestive linkage of 12LS to chromosomes 5 (LOD = 2.18)
and 20 (LOD = 2.12). Linkage results for the principal
component analysis of the LVH measures showed one
significant LOD score for PC2 on 15q11.2 (LOD = 3.01).
This region was also linked to SL (LOD = 1.92). Two
regions were suggestively linked to PC1: 11q13.4
(LOD = 2.01) and 20p12.1 (LOD = 2.83), which was
also linked to SL and 12LS. For PC2, there were
three suggestive linkage results, for chromosomes 6
(LOD = 2.09), 9 (LOD = 2.35) and 22 (LOD = 1.99).
The chromosome 6 region was also linked to CV.
Plots showing the linked regions by chromosome are
provided in Fig. 1. Table 5 shows the top common
variant microarray-based association signals under the
LVH trait linkage peaks, including P-values and MAF
for each SNP. None achieved statistical significance
after correction for multiple comparisons.
Variants in the coding sequence
The results of the search for less frequent exonic variants
are summarized in Additional file 1: Table S1. We focused
on relatively rare (frequency < 5%) missense variants pre-
dicted to be deleterious by at least two of the prediction
algorithms used and non-sense variants. This selection
yielded 471 variants in 356 genes in the 13 linkage inter-
vals (LOD-2 SI), which we analysed with respect to the
LVH proxy measures and PCs. Additional file 1: Table S2
shows the results with a nominal P-value ≤0.05 after
regressing out the effects of age, BMI, height and sex. This
effort uncovered an A >G variation (rs139580877) in the
SPEF2 gene on 5p13.2, which was significantly associated
Table 1 Descriptive statistics of the Erasmus Rucphen Family (ERF) study population
Microarray Linkage Exon sequence
n = 2128 n = 1860 n = 1072
Mean (S.D.) Minimum Maximum Mean (S.D.) Minimum Maximum Mean (S.D.) Minimum Maximum
Males 899 (42%) 775 (42%) 408 (38%)
Age (y) 47.0 (13.82) 16.6 85.3 46.5 (13.79) 16.6 85.3 46.51 (13.7) 18.7 81.0
BMI (kg/m2) 26.7 (4.57) 15.5 61.8 26.7 (4.58) 15.5 61.8 26.4 (4.3) 15.5 61.8
Height (cm) 167.6 (9.31) 139.3 196.5 167.4 (9.19) 143.6 196.5 166.7 (9.0) 143.6 196.5
Weight (kg) 75.1 (15.16) 41.9 161.0 74.9 (15.5) 41.9 161 73.6 (14.3) 42.1 161.0
SBP (mm Hg) 138.4 (19.5) 85.5 222.0 137.7 (19.1) 85.5 217.0 137.0 (18.7) 85.5 216.0
DBP (mm Hg) 79.9 (9.8) 53.5 124.0 79.7 (9.7) 54.5 120.0 79.1 (9.6) 53.5 120.0
Hypertension 913 (43%) 766 (42%) 549 (51%)
SL 2344 (690.6) 884.0 5288.0 2341 (690.6) 884 52.9 2319 (659.0) 967 5288.0
CV 1173.5 (505.1) 93.1 4126.1 1170.0 (497.3) 93.1 3952.8 1151.6 (659.0) 155.8 3853.0
12LS 13,862 (3812.3) 4993 39,250 13,805 (3767.8) 49.9 39.2 13,610.0 (3628.7) 5485.0 36,364
LVH (SL) 138 (6.5%) 120 (6.4%) 66 (6.2%)
LVH (CV) 41 (1.9%) 32 (1.7%) 20 (1.9%)
LVH (12LS) 176 (8.3%) 147 (7.9%) 76 (7.1%)
Values presented are mean (standard deviation) or n (%)
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, SL Sokolow-Lyon index, CV Cornell product, 12LS 12-lead sum product
Table 2 Pearson’s correlations between LVH proxy measures
Unadjusted Adjusted
SL – 12LS 0.80 0.76
SL – CV 0.29 0.17
CV – 12LS 0.56 0.48
Adjusted model included age, sex, body-mass index, and height
SL Sokolow-Lyon, CV Cornell Voltage product, 12LS twelve-lead sum product,
PC1 first principal component, PC2 second principal component
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with 12LS when adjusted for multiple testing (P-value =
4.2 × 10− 4). This variant, with 108 carriers in ERF, is pre-
dicted to be probably damaging by PolyPhen-2 with a
score of 0.972 and as deleterious by SIFT with a score ran-
ging between 0.02 and 0.03. It is a missense variant,
among more than 2000 described for this gene. In the
principal components analysis, rs138968470, on 11q13.1 in
the MAP3K11 gene, was associated with PC1 adjusted for
multiple testing (P-value = 3.5 × 10− 4). SKAT-O and burden
tests provided some supporting evidence for the association
of this gene with LVH proxy measures (Additional file 1:
Table S3). Additionally, at the SL chromosome 4 locus, we
identified a C >G variation (rs142551296) in PRSS12 that
approached significance (P-value = 8.4 × 10− 4). A second,
more common intragenic variant inside PRSS12 was nom-
inally associated (rs35996030; P-value = 0.04). We re-ran
the linkage analyses conditioning on these variants to see if
they explained the observed linkage signals. For PC1, the
LOD score in the 11q13.4 linkage region dropped in the
conditional analysis (from 2.01 to 0.88), suggesting that
the associated variant (rs138968470), or neighbouring
variants in linkage disequilibrium (LD), explained the link-
age signal. This variant also showed evidence of associ-
ation with the two traits (12LS and SL) underlying PC1
(P-value = 3.0 × 10− 4 and P-value = 1.2 × 10− 3, respect-
ively). Using Gene Network (http://genenetwork.nl/gene/
ENSG00000173327), to perform in-depth analyses of the
expression of MAP3K11, demonstrated that its expression
is strongly linked to rho signalling (ARGHGEF15, ARHG-
DIA) (Fig. 2).
Five of the linkage peaks contained loci recently
identified in GWAS studies [5, 11]. To determine if the
linkage signals were a result of those common variants,
linkage was performed a second time, conditioned on
the GWAS index SNPs. These analyses demonstrated
that the observed peaks were not explained by the
GWAS SNPs, although the estimates fluctuated some-
what, likely as a result of smaller sample sizes
(Additional file 1: Table S4).
Replication
Summary statistics for the Rotterdam Study sample
are provided in Additional file 1: Table S5. The vari-
ant rs139580877 was imputed, using the 1000
Genomes reference panel; the imputation quality
score (MACH RSQ) for this variant was 0.65, with a
minor allele frequency of 0.008. The effect estimate
for 12LS was essentially zero, and therefore, did not
replicate the ERF findings (Additional file 1: Table S6).
The other variants of interest, rs35996030, rs138968470
and rs142551296, were directly genotyped in a subset of
the Rotterdam Study cohort (n = 1450). There was no
Table 4 Results of the linkage analyses
Trait N Chr. SNP LOD-2 SI Lower LOD-2 SI Upper Position (cM) LODMAX
SL 1860 4 rs1032328 90,166,159 157,272,456 144.46 2.14
SL 1860 15 rs290370 88,026,435 102,212,431 112.3 1.92
SL 1860 20 rs204115 11,094,951 23,352,685 38.11 2.64
CV 1860 1 rs6619 12,296,232 53,396,842 59.63 2.40
CV 1860 6 rs2040431 72,253,060 117,799,468 108.31 2.17
12LS 1860 5 rs1442470 7,205,420 25,399,905 42.3 2.18
12LS 1860 20 rs466243 11,017,796 23,352,685 40.7 2.12
PC1 1860 11 rs1530354 33,896,047 78,743,080 65.21 2.01
PC1 1860 20 rs2077147 11,990,037 38,247,165 45.09 2.83
PC2 1860 6 rs1391503 87,511,828 105,402,837 99.69 2.09
PC2 1860 9 rs748530 8,378,662 25,788,723 40.22 2.35
PC2 1860 15 rs1562203 – 23,707,591 0 3.01
PC2 1860 22 rs138383 35,687,558 44,707,606 46.89 1.99
Model adjusted for age, sex, body-mass index, and height
SL Sokolow-Lyon, CV Cornell Voltage product, 12LS twelve-lead sum product, PC1 first principal component, PC2 second principal component, N sample size, Chr.
chromosome, LOD-2 SI Lower position of lower boundary of support interval in base pairs, LOD-2 SI Upper position of upper boundary of support interval in base
pairs, LODMAX LOD score at SNP
Table 3 PC loadings for LVH proxies
Principal Component
PC1 PC2
SL 0.84 −0.48
CV 0.61 0.78
12LS 0.95 −0.08
Adjusted model included age, sex, body-mass index, and height
SL Sokolow-Lyon, CV Cornell Voltage product, 12LS twelve-lead sum product,
PC1 first principal component, PC2 second principal component
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Fig. 1 Linkage peaks for the LVH proxy measures. Plots depicting the linked regions by trait and chromosome. The grey dashed horizontal line
indicates the threshold for suggestive linkage. The red dashed vertical lines show the borders of the LOD score minus 2 support intervals (LOD-2
SI). The blue circles contain SNPs identified in previous GWAS for these traits in the LOD-2 SI
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evidence of association for any of these variants in the
Rotterdam Study.
Discussion
We performed a linkage study on LVH proxy measure-
ments, and PCs, and identified one significant locus
(15q11.2) and 10 suggestive regions (1p34, 4q31, 5p14,
6q15, 6q21, 9p21, 11q13.4, 15q25, 20p12, 22q13). Exome
variant analysis in these regions uncovered a missense
coding variation in MAP3K11 on 11q134 for PC1; the
MAP3K11 variant substantially decreased the LOD score
for this peak. The 24 carriers of this missense mutation
clustered into five pedigrees in the ERF population
(Additional file 1: Figure S2).
Genetic variants discovered by GWAS, based on indi-
vidual single-nucleotide polymorphisms (SNPs), explain
only a small proportion of the heritability of complex
traits [10, 39, 40]; we found variants with larger effect
sizes compared to the ones found with GWAS. Our ana-
lysis of rare coding variants in these linkage regions re-
vealed a variant, rs138968470 on 11q13.1 in the
MAP3K11 gene, associated with PC1. Conditional link-
age analysis, including the MAP3K11 variant, reduced
the LOD score (from 2.01 to 0.88), suggesting that this
variant largely explained the linkage signal at this
chromosomal location. The SNP is located in the first
exon of a gene encoding a protein that belongs to the
serine/threonine kinase family of mitogen-activated pro-
tein kinases. MAP3K11 (also known as Mixed Lineage
Kinase 3 (MLK3)) [34], works as a positive regulator of
the c-Jun N-terminal kinase (JNK) signalling pathway
[41]. MAP3K11 has a CDC42 and Rac interacting pro-
teins binding domain (CRIB); autophosphorylation of
MAP3K11 and the induction of JNK is mediated through
this CRIB domain bound to Cdc42/Rac/GTP [42]. JNK,
an important member of the mitogen-activated protein
kinase family (MAPK), is a pro-apoptotic kinase that plays
an important role in the induction of cardiomyocyte apop-
tosis in various pathologies [43]. Apoptosis increases with
LVH, a critical mechanism that mediates the transition
from compensated hypertrophy to heart failure [44]. In
this way, a damaging mutation in MAP3K11 may be
related to regulation of JNK and the subsequent JNK con-
trolled pathway.
The other significant missense variant was rs139580877,
located on 5p14. This variant is in exon 9 of the gene that
encodes the sperm flagellar protein (SPEF2), which has
been postulated to play an important role in spermatogen-
esis and flagellar assembly [45]. This SNP was not found
to be responsible for the linkage signal in the region, des-
pite its strong association. The association with this rela-
tively common variant (MAF = 0.015) could not be
confirmed in the Rotterdam Study. One additional finding
was studied further: a C/G variant (rs142551296) in the
PRSS12 gene, underlying the SL locus on chromosome 4,
which approached significance (P-value = 8.4 × 10− 4), but
did not replicate in the Rotterdam Study. Absence of repli-
cation could be related to imputation quality for
rs139580877 and the low number of carriers for the other
SNPs (Additional file 1: Table S4).
A number of the linkage peaks contained SNPs identi-
fied in a large GWAS of these traits. Linkage analysis,
conditioned on the index SNPs from the GWAS, did not
significantly alter the linkage results. This suggests that
the linkage peaks were not driven by the common vari-
ants identified in the GWAS.
Table 5 Top association signals from the microarray data under the LVH trait linkage peaks
Outcome Region SNP MAF Gene P-value Q-value
SL 4q26 rs6839953 0.27 TRAM1L1 1.34 × 10−4 0.47
SL 15q26.2 rs11074275 0.48 MCTP2 4.27 × 10−4 0.79
SL 20p12.1 rs721243 0.19 ISM1 7.37 × 10−5 0.15
CV 1p35.1 rs16835131 0.06 SYNC 1.35 × 10−5 0.35
CV 6q15 rs10944412 0.27 RNGTT 4.60 × 10−5 0.93
12LS 5p15.2 rs2589661 0.10 ROPN1L 1.26 × 10− 4 0.46
12LS 20p11.23 rs6106235 0.18 C20orf26 1.69 × 10−5 0.09
PC1 11q12.2 rs1790325 0.04 FADS1 2.85 × 10−5 0.08
PC1 20p12.1 rs13036282 0.005 SPTLC3 2.30 × 10−4 0.63
PC2 6q16.3 rs1475922 0.06 GRIK2 1.64 × 10−4 0.94
PC2 9p24.1 rs10975939 0.003 KDM4C 4.67 × 10−4 1.00
PC2 15q11.2 rs8043191 0.03 CYFIP1 5.95 × 10−3 0.52
PC2 22q13.33 rs2688089 0.45 C22orf34 7.02 × 10−5 0.56
SL Sokolow-Lyon, CV Cornell Voltage product, 12LS twelve-lead sum product, PC1 first principal component, PC2 second principal component, MAF minor
allele frequency
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No explanatory variants were found for most of the
loci (suggestively) linked to LVH, for which there are a
number of potential explanations. Linkage peaks are not
precise in highlighting the location of the causal variant;
even the region of interest cannot be easily pinpointed.
Additionally, we did not take into account alternative
mechanisms, such as structural and copy number var-
iations (CNVs) or repeats in the linkage regions.
Lastly, causal rare variants may be located outside the
coding sequence, which we did not include in our
sequencing analyses.
Conclusions
In conclusion, 13 loci were identified for ECG LVH proxy
measures and PCs using linkage analysis in a large pedigree;
these were subsequently fine-mapped with microarray and
exome sequence data. Common variation from the micro-
arrays did not explain these peaks. The exome data, though,
suggested the involvement of MAP3K11 (11q13) in LVH
through the regulation of JNK. However, we cannot exclude
the presence of other variants that are in linkage disequilib-
rium with the MAP3K11 variant (rs138968470) that might
explain the observed association.
Fig. 2 MAP3K11 gene network interactions. Looking for interactions for MAP3K11, we searched Gene Network (http://genenetwork.nl/gene/
ENSG00000173327). One hundred twenty-nine gene-gene interactions are shown
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Further analysis will need to be performed to demon-
strate the involvement of this protein in LVH. A number
of other suggestively linked peaks were determined. We
could not explain these with microarray or exonic se-
quence variants at present, asking for more extensive
follow-up outside the coding regions.
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